Lyman on Bringing Biosimilars From Bench to Bedside in Oncology

Nov 02, 2020, 07:41 PM

In our exclusive interview, Gary H. Lyman, MD, MPH, discusses the current state of biosimilars in oncology, the pathways that have been established to ensure the safe delivery of these agents to patients, and the potential effects they could have on alleviating some of the current constraints within the health care system.